Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company which develops and commercializes products in the therapeutic areas of allergy and respiratory disease. The Company's specialty pharmaceutical product candidates comprise pre-filled syringe for use in the emergency treatment of acute allergic reactions, and inhaler products for the treatment of bronchospasm, asthma and chronic obstructive pulmonary disease. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients.

Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
14 (est)
Adamis Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

CEO
Robert O. Hopkins

Robert O. Hopkins

CFO
Ronald Moss

Ronald Moss

CMO
Thomas Moll

Thomas Moll

VP of Research
David Marguglio

David Marguglio

SVP of Corporate Development

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
11682 El Camino Real, Suite # 300
Show all (1)
Report incorrect company information

Adamis Pharmaceuticals Financials and Metrics

Adamis Pharmaceuticals Financials

Adamis Pharmaceuticals's revenue was reported to be $13.07 m in FY, 2017
USD

Revenue (FY, 2017)

13.1 m

Gross profit (FY, 2017)

5.7 m

Gross profit margin (FY, 2017), %

43.2%

Net income (FY, 2017)

(25.5 m)

EBIT (FY, 2017)

(24.8 m)

Market capitalization (23-Apr-2018)

106.5 m

Cash (31-Dec-2017)

17.3 m

EV

91.8 m
Adamis Pharmaceuticals's current market capitalization is $106.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

6.5 m13.1 m

Cost of goods sold

4.9 m7.4 m

Gross profit

1.6 m5.7 m

Gross profit Margin, %

25%43%
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.9 m2.1 m3 m3.8 m3.4 m

Cost of goods sold

1.3 m1.8 m1.7 m1.9 m2.1 m

Gross profit

582.1 k254.5 k1.4 m1.9 m1.3 m

Gross profit Margin, %

30%12%45%51%38%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.4 m4.1 m4.1 m17.3 m

Accounts Receivable

805.4 k830.1 k

Inventories

14.5 k71 k942.1 k1.8 m

Current Assets

4.2 m21.5 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

119.6 k4.7 m2.1 m5.9 m11.2 m8.5 m6.3 m4.4 m417.1 k7.8 m399.5 k10.7 m23.3 m

Accounts Receivable

744.7 k595.6 k1.2 m1.2 m1 m

Inventories

1.2 m1.1 m914.2 k950 k996.1 k

Current Assets

2.2 m6 m11.3 m8.5 m6.4 m5 m2.6 m10.7 m26.5 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Depreciation and Amortization

888.4 k2.5 m3.1 m

Inventories

14.5 k(165 k)1.9 k(882.5 k)

Accounts Payable

671 k116 k(1.7 m)587.2 k

Cash From Operating Activities

5.4 m306 k
Quarterly
USDQ1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Inventories

1.2 m914.2 k

Accounts Payable

547.7 k750 k977.2 k498 k408.8 k1.5 m4.2 m1.7 m2.7 m
USDY, 2017

EV/EBIT

-3.7 x

Revenue/Employee

912.1 k

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

Adamis Pharmaceuticals News and Updates

Report incorrect company information